Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective. Innate Pharma SA

IPHA

RBC Capital Maintains Outperform on Danaher, Raises Price Target to $317

By Benzinga Newsdesk

Today, 12:56 PM

RBC Capital analyst Deane Dray maintains Danaher (NYSE:DHR) with a Outperform and raises the price target from $301 to $317.

DHR

William Blair Upgrades FibroGen to Outperform

By Benzinga Newsdesk

Today, 12:56 PM

William Blair analyst Andy Hsieh upgrades FibroGen (NASDAQ:FGEN) from Market Perform to Outperform.

FGEN

Nomura Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $84

Related Posts

Disney To Resume Caribbean Cruises In August

Innate Pharma Announces HSR Clearance Regarding Expansion Of Its Collaboration With Sanofi On NK Cell Engagers

RBC Capital Maintains Outperform on Danaher, Raises Price Target to $317

William Blair Upgrades FibroGen to Outperform